ABSTRACT
Purpose
A proportion of patients with localized prostate cancer is still treated with primary androgen deprivation therapy (PADT) alone. Some of these patients may develop a PSA rising despite castration. The purpose of this study was to retrospectively evaluate the potential benefit of external beam radiotherapy (EBRT) in this cohort.
Methods
Forty-two patients presenting a non-metastatic castration-resistant prostate cancer after PADT were referred to our institution and underwent RT between June 2003 and July 2011. Biochemical failure (BF) after EBRT was defined according to Phoenix criteria (nadir + 2 ng/mL “at call”). Median RT dose was 78 Gy.
Results
Median duration of PADT was 54 months (range 10.2–181 months). Median follow-up after EBRT was 53 months. Twenty-one patients had BF after EBRT (median time 27.4 months): 13 presented with loco-regional and/or distant metastases, while in 8 patients, a PSA rise only was observed. Ten patients died of prostate cancer (and no patient died of causes other than prostate cancer). Five-year biochemical disease-free survival (bDFS), distant metastases-free survival (DMFS) and cancer-specific survival (CSS) were, respectively, 39.4, 60 and 65 %. On multivariate analysis, GS, nadir PSA (nPSA) and a pre-EBRT PSA ≤5 ng/mL significantly affected bDFS, while Gleason score (GS) and T stage significantly affected distant metastases onset. No factors affected CSS at multivariate analysis.
Conclusions
EBRT may be a suitable therapeutic option, able to provide an excellent loco-regional control and to obtain a systemic disease control in up to 60 % of patients at 5 years, especially in patients presenting with lower Gleason score and T stage at diagnosis and lower pre-RT PSA and nPSA post-RT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Akimoto T, Kitamoto Y, Saito J et al (2004) External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes. Int J Radiat Oncol Biol Phys 59:372–379
Cooperberg MR, Broering JM, Carroll PR (2010) Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117–1123
Gogna NK, Baxi S, Hickey B et al (2012) Split-course, high-dose palliative pelvic radiotherapy for locally progressive hormone-refractory prostate cancer. Int J Radiat Oncol Biol Phys 83:e205–e211
Guarneri A, Botticella A, Ragona R et al (2013) Prostate-specific antigen kinetics after I125-brachytherapy for prostate adenocarcinoma. World J Urol 31:411–415
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
Ko EC, Stone NN, Stock RG (2012) PSA nadir of <0.5 ng/mL following brachytherapy for early stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys 83:600–607
Lankford SP, Pollack A, Zagars GK (1995) Radiotherapy for regionally localized hormone refractory prostate cancer. Int J Radiat Oncol Biol Phys 33:907–912
Mohler JL, Armstrong AJ, Bahnson RR et al (2012) Prostate cancer, version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 10:1081–1087
Nakamura K, Teshima T, Takahashi Y et al (2004) Radiotherapy for localized hormone-refractory prostate cancer in Japan. Anticancer Res 24:3141–3146
Oefelein MG, Agarwal PK, Resnick MI (2004) Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. J Urol 171:1525–1528
Ogawa K, Nakamura K, Sasaki T et al (2009) External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months. Int J Radiat Oncol Biol Phys 74:759–765
Ray ME, Thames HD, Levy LB et al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:40–50
Roach MIII, Hanks G, Thames H et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974
Sanguineti G, Marcenaro M, Franzone P et al (2004) Is there a “Curative” role of radiotherapy for clinically localized hormone refractory prostate cancer. Am J Clin Oncol 27:264–268
Sasaki T, Nakamura K, Ogawa K et al (2009) Radiotherapy for patients with localized hormone-refractory prostate cancer: results of the patterns of care study in Japan. BJU Int 104:1462–1466
Shamash J, Davies A, Ansell W et al (2008) A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br J Cancer 98:22–24
Smith MR, Kabbinavar F, Saad F et al (2005) Natural history of rising serum prostate-specific antigen in men with castrate non metastatic prostate cancer. J Clin Oncol 23:2918–2925
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Botticella, A., Guarneri, A., Filippi, A.R. et al. May non-metastatic clinically localized castration-resistant prostate cancer after primary androgen ablation benefit from salvage prostate radiotherapy?. J Cancer Res Clin Oncol 139, 1955–1960 (2013). https://doi.org/10.1007/s00432-013-1520-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-013-1520-3